Arrowhead Falls 15% on Pancreatitis Win; Insiders Sold
Arrowhead's plozasiran reduced pancreatitis event rates 78% in Phase 3 trials, but the stock fell 15% on the news, closing at $48.81. Two directors sold shares at $87 in August—79% above current price
Plozasiran Cuts Pancreatitis 78%; ARWR Falls 15%
NEW YORK, November 9 —
Arrowhead Pharmaceuticals, Inc. (ARWR) delivered Phase 3 data at the American Heart Association's 2026 Scientific Sessions showing plozasiran cut acute pancreatitis event rates by 78% versus placebo, and the stock fell 15% anyway, landing at $48.81, more than $38 below the price where two company directors quietly sold $1.19 million worth of shares just three months ago.
- Plozasiran reduced acute pancreatitis event rates 91% versus placebo in the highest-risk sHTG subset across pooled SHASTA-3/4 data. [source]
- ARWR trades at $48.81 against analyst consensus target of $107.71, a 55% discount to consensus.
- Directors Olukotun and Perry sold a combined $1.19 million in shares at approximately $87 on August 18, 2026.
Strong Data, Wrong Story
The AHA presentation was not a failure by clinical standards. The pooled SHASTA-3 and SHASTA-4 analysis showed 91% event-rate reduction in severe hypertriglyceridemia patients with a prior pancreatitis history, a population with few alternatives. The PALISADE open-label extension added durability: sustained triglyceride and APOC3 reductions through 36 months. A planned filing for the same indication already qualified for a six-month FDA review. The clinical package is coherent and the regulatory path is shortened. What the data does not resolve is whether the pancreatitis indication, a relatively rare, high-severity condition, anchors the cardiovascular blockbuster thesis the stock has historically been priced on.
The August Exit at $87
The insider timing invites scrutiny. On August 18, 2026, Director Michael S. Perry sold 11,600 shares at $87.30 for proceeds of $1,012,680, while Director Adeoye Y. Olukotun sold 2,000 shares at $86.96 for $173,920, both open-market transactions, per their SEC filings. No insider purchases have been recorded in the past 90 days. The two directors exited at prices 79% above where the stock trades today. Meanwhile, Arrowhead's most recent quarter missed EPS consensus by 10.5% (-$1.36 reported versus -$1.23 expected), following a quarter that beat by 160% on lumpy milestone revenue, a pattern that makes earnings momentum difficult to track. The company holds $1.60 billion in cash against $1.38 billion in debt, and free cash flow is negative $49 million.
| Ticker | Mkt cap | Fwd P/E | 52-wk |
|---|---|---|---|
| ARWR | $6.9B | n/a | +45.9% |
| ALNY | $21.0B | 14.5x | -64.7% |
| IONS | $5.2B | n/a | -43.3% |
| AXSM | $7.0B | 39.7x | -3.9% |
| ACAD | $3.1B | 17.0x | -4.4% |
| SRPT | $1.9B | 8.1x | +3.2% |
What the Next Checkpoint Reveals
Arrowhead's TRiM platform spans liver, lung, muscle, adipose, and central nervous system targets, with collaboration revenue from GlaxoSmithKline, Takeda, Amgen, and Sarepta. The pipeline also includes ARO-DIMER-PA, an early-stage dual-functional molecule that produced mean LDL-C reductions of 65% and median triglyceride reductions of 78% in single-dose Phase 1/2a data, positioning it as a potential single-agent treatment for mixed hyperlipidemia. Whether the FDA accepts the plozasiran filing under six-month accelerated review, and whether cardiovascular outcome data emerges to support a broader label claim beyond pancreatitis prevention, are the near-term tests for the stock. Run the free Arrowhead Pharmaceuticals, Inc. deep-dive →
Current fundamentals, valuation and filing history for Arrowhead Pharmaceuticals, Inc. (ARWR) are tracked on its Basis Report page.
Basis Report is independent research for informational purposes. It is not investment advice and not a recommendation to buy or sell any security.
Frequently Asked Questions
Does Arrowhead's plozasiran reduce pancreatitis?
Yes. Phase 3 data from the pooled SHASTA-3/4 analysis showed plozasiran reduced acute pancreatitis event rates 91% versus placebo in patients with severe hypertriglyceridemia and a prior pancreatitis history. The company has already qualified for six-month FDA accelerated review.
Why did the stock fall despite strong clinical data?
The clinical data is strong by FDA standards, but the market questions whether pancreatitis, a relatively rare, high-severity condition, anchors the cardiovascular blockbuster thesis historically priced into the stock. Arrowhead trades 55% below analyst consensus target of $107.71, signaling broader doubt beyond the clinical readout.
When and why did the insider selling occur?
On August 18, 2026, Director Michael S. Perry sold 11,600 shares at $87.30, and Director Adeoye Y. Olukotun sold 2,000 shares at $86.96. Both exited at prices 79% above current levels, and no insider purchases have been recorded in the past 90 days.
What other assets does Arrowhead have?
The company's TRiM platform spans liver, lung, muscle, adipose, and central nervous system targets with collaboration revenue from GlaxoSmithKline, Takeda, Amgen, and Sarepta. Early-stage ARO-DIMER-PA produced mean LDL-C reductions of 65% and median triglyceride reductions of 78% in Phase 1/2a data.
What is Arrowhead's financial position?
Arrowhead holds $1.60 billion in cash against $1.38 billion in debt, though free cash flow is negative $49 million. The company's most recent quarter missed EPS consensus by 10.5%.
Arrowhead Pharmaceuticals' plozasiran cut acute pancreatitis event rates by 78% versus placebo in Phase 3 pooled data unveiled at the American Heart Association's 2026 Scientific Sessions — yet ARWR shares fell 15% on November 9, leaving the stock at $48.81 against an analyst consensus target of $107.71.